Revelation Biosciences Inc (REVB) — Cash Flow-to-Debt Ratio
Revelation Biosciences Inc (REVB) has a Cash Flow-to-Debt Ratio of -1.56x as of March 2026, meaning its operating cash flow of $-3.21 Million could theoretically repay -2% of its total liabilities ($2.06 Million) in one year. Explore long-term investment intensity of Revelation Biosciences Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Revelation Biosciences Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Revelation Biosciences Inc across 10 annual periods. Also explore Revelation Biosciences Inc assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Revelation Biosciences Inc (2016–2025)
Year-by-year debt coverage analysis for Revelation Biosciences Inc. For market capitalisation and broader financial context, see REVB market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.04x | $-8.27 Million | $2.72 Million | ▲ +68.3% |
| 2024 | -9.57x | $-18.32 Million | $1.91 Million | ▼ -631.2% |
| 2023 | -1.31x | $-7.29 Million | $5.56 Million | ▲ +48.1% |
| 2022 | -2.52x | $-11.22 Million | $4.45 Million | ▲ +51.3% |
| 2021 | -5.18x | $-11.09 Million | $2.14 Million | ▼ -2810.4% |
| 2020 | -0.18x | $-215.07K | $1.21 Million | ▼ -100.0% |
| 2019 | 1561.67x | $41.09 Million | $26.31K | ▲ +10499175.7% |
| 2018 | 0.01x | $32.58 Million | $2.19 Billion | ▲ +17.2% |
| 2017 | 0.01x | $24.25 Million | $1.91 Billion | ▲ +88.8% |
| 2016 | 0.01x | $11.60 Million | $1.73 Billion | — |